BioCardia, Inc. announced on October 2, 2025, that it has regained compliance with the Nasdaq Capital Market’s Listing Requirements. This confirmation follows the company’s successful efforts to improve its balance sheet and raise new capital.
Specifically, on October 1, 2025, BioCardia received written notice from Nasdaq confirming compliance with Listing Rule 5550(b)(1), known as the Equity Rule. This means the company's securities will continue to be listed on the Nasdaq Capital Market under the symbol 'BCDA'.
Regaining compliance removes the substantial doubt about the company's ability to continue as a going concern and eliminates the threat of delisting. This development is expected to enhance investor confidence and support the company's ongoing development of therapeutic candidates and approved products.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.